For the quarter ending 2026-03-31, SPRY made $22,681K in revenue. -$60,839K in net income. Net profit margin of -268.24%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 22,681 | 28,087 | 32,501 | 15,717 |
| Cost of goods sold (including related party amounts of 1,233 and 488, respectively) | 6,286 | 6,154 | 8,191 | 4,984 |
| Research and development (including related party amounts of 667 and 666, respectively) | 4,336 | 3,443 | 2,751 | 4,035 |
| Selling, general and administrative (including related party amounts of 135 and 124, respectively) | 72,204 | 59,955 | 74,751 | 54,312 |
| Total operating expenses | 82,826 | 69,552 | 85,693 | 63,331 |
| Loss from operations | -60,145 | -41,465 | -53,192 | -47,614 |
| Interest income | 1,968 | 711* | - | - |
| Interest expense (including related party amounts of 122 and 0, respectively) | 2,441 | 650* | - | - |
| Total other (expense) income, net | -473 | 61 | 2,041 | 2,731 |
| (loss) income before income tax (benefit) expense | - | -41,344* | - | - |
| Income tax (benefit) expense | - | -20* | - | - |
| Net loss | -60,618 | -41,324 | -51,151 | -44,883 |
| Unrealized gaines on available-for-sale securities | -221 | 132 | 39 | -118 |
| Comprehensive loss | -60,839 | -41,192 | -51,112 | -45,001 |
| Basic EPS | -0.61 | -0.416 | -0.52 | -0.46 |
| Diluted EPS | -0.61 | -0.416 | -0.52 | -0.46 |
| Basic Average Shares | 99,296,408 | 99,035,917 | 98,807,600 | 98,361,771 |
| Diluted Average Shares | 99,296,408 | 99,035,917 | 98,807,600 | 98,361,771 |
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)